|
|
|
|
|
Nizatidine
drug data and news
Nizatidine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Nizatidine | ||
| Brand Names/Synonyms | Acinon; Antizid; Axid; Axid Ar; BRN 4846056; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; HSDB 3574; LY 139037; NIZATIDINE; Naxidine; Niatidine; Nizatidina [Spanish]; Nizatidine; Nizatidine [Usan:Ban:Inn:Jan]; Nizatidinum [Latin]; Nizax; Nizaxid; Panaxid; Splendil Er; Tazac; Ulcosol; Ulxid; ZE-101; ZL-101; Zanizal; Zinga | ||
| Indication | For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers. | ||
| Mechanism Of Action | Nizatidine competes with histamine for binding at the H2-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin. | ||
| Nizatidine News (When available) |
Common practice of prescribing H2 blockers to treat acid reflux in ... Feb 24, 2006 H 2 Blockers in Preemies Raise Necrotizing Enterocolitis Risk Feb 9, 2006 H 2 Blockers in Preemies Raise Necrotizing Enterocolitis Risk 09 Feb 2006 Common Reflux Treatment Linked to Life Threatening Bowel Infection ... 09 Feb 2006 Booster shot Dec 4, 2005 Holiday Treats Present Temptations and Challenges for Children ... Nov 22, 2005 Holiday Treats Present Temptations and Challenges for Children ... Nov 22, 2005 Holidays Present Challenges for Children With GERD Nov 23, 2005 DRL gets FDA approval for nizatidine Sep 19, 2005 Dr. Reddy's Labs gets FDA approval for nizatidine Sep 18, 2005 Shasun Drugs: Strengthening presence Sep 26, 2005 Indian shares top 8,400 for first time Sep 19, 2005 Dr. Reddy's gets FDA approval Sep 20, 2005 Oil and Metal stocks take Sensex past 8400 Sep 19, 2005 Cheap branded drugs soon available in Botika ng Bayan Sep 9, 2005 Zeria Pharmaceutical Brings Nizatidine-based OTC Gastrointestinal ... Jun 15, 2005 Reliant Pharmaceuticals Announces the Sale of Axid(R) Oral ... Jun 30, 2005 Braintree Laboratories Increases Presence in the Pediatric Market Jun 30, 2005 Shasun Chemicals expands product-base Jun 7, 2005 Zeria Pharmaceutical Brings Nizatidine-based OTC Gastrointestinal ... Jun 15, 2005 Shasun Chemicals expands product-base Jun 7, 2005 Glenmark, Shasun to sell generics in the US Mar 28, 2005 Heartburn Drugs Linked to Pneumonia Feb 11, 2005 | ||
| Dosage Forms | CAPSULE (150, 300 mg) | ||
| Drug_Category | Anti-ulcer Agents; Histamine H2 Antagonists; ATC:A02BA04 | ||
| Absorption | Rapid (bioavailability of nizatidine exceeds 70%) | ||
| Interactions |
Interactions for Nizatidine: No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin. Nizatidine does not inhibit the cytochrome P-450-linked drug-metabolizing enzyme system; therefore, drug interactions mediated by inhibition of hepatic metabolism are not expected to occur. In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently. | ||
| Toxicity | Oral, rat LD50: 301 mg/kg. Symptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitro-ethene-1,1-diamine | ||
| Chemical Formula | C12H21N5O2S2 | ||
| Molecular Weight | 331.46 g/mol | ||
| Smiles String | CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C | ||
| Melting Point | 203 °C | ||
| Water Solubility | 10-33mg/mL | ||
| State | Solid (off-white to buff crystals) | ||
| LogP/Hphobicity | 1.506 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose). | ||
| Half Life | 1-2 hours | ||
| Protein Binding [%] | 35% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Nizatidine.html http://www.rxlist.com/cgi/generic/nizat.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00706 | ||
| CAS Registry Number | 76963-41-2 | ||
| KEGG Compound ID | C07270 | ||
| PubChem ID | SID:191384 | ||
| PharmGKB ID | PA450646 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2246046 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |